SSTR靶向PET放射性配体估算分肾功能的研究
本研究回顾性纳入85例接受[177Lu]Lu-DOTA-TATE治疗的神经内分泌肿瘤患者,评估治疗前SSTR-PET/CT肾脏摄取是否反映分肾或整体肾功能,并与[99mTc]Tc-MAG3闪烁显像及肾脏吸收剂量比较。结果显示PET摄取与分肾功能中度相关,但与整体肾功能指标无相关,提示PET/CT估算分肾功能和吸收剂量潜力有限。
要点
- SSTR-PET/CT肾脏SUVmean与[99mTc]Tc-MAG3分肾功能中度相关。
- 总肾脏PET摄取与TER、eGFR或血肌酐无相关。
- PET摄取与肾脏吸收剂量中度相关,仅[18F]SiTATE组TER与剂量强负相关。
核心结论
- SSTR-PET/CT在估算治疗前分肾功能和肾脏吸收剂量方面显示中度潜力,但不能可靠估算整体肾功能。
研究设计与样本
- 回顾性研究纳入2013至2023年间接受[177Lu]Lu-DOTA-TATE治疗的85例神经内分泌肿瘤患者,均行SSTR-PET/CT([18F]SiTATE、[68Ga]Ga-DOTA-TATE或[68Ga]Ga-DOTA-TOC)、血清肾功能检测和[99mTc]Tc-MAG3闪烁显像,其中30例用治疗后SPECT/CT估算肾脏吸收剂量。
主要发现
- 肾脏PET摄取与[99mTc]Tc-MAG3评估的分肾功能在所有示踪剂中均呈中度相关,尤其使用SUVmean时:[18F]SiTATE(r=0.462;p=0.010)、[68Ga]Ga-DOTA-TATE(r=0.515;p=0.004)、[68Ga]Ga-DOTA-TOC(r=0.546;p=0.004)。
- 总肾脏PET摄取与肾小管提取率、eGFR或血清肌酐之间未观察到相关。
- 肾脏PET摄取与平均吸收剂量在选定示踪剂队列中呈中度相关:[18F]SiTATE(r=0.585;p=0.076)、[68Ga]Ga-DOTA-TATE(r=0.649;p=0.049)。
- 仅在[18F]SiTATE组观察到肾小管提取率与吸收剂量之间强负相关(r=-0.768;p=0.010)。
临床怎么用
- SSTR-PET/CT或可用于辅助估算分肾功能和肾脏吸收剂量,但不宜单独用于评估整体肾功能。
- 基于PET/CT的肾脏评估用于个体化PRRT规划前需更大规模研究验证。
局限性
- 本研究为回顾性设计。
- 肾脏吸收剂量仅在30例患者中估算。
- 部分示踪剂队列样本量有限,相关性分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SSTR-PET is routinely used to select patients with neuroendocrine neoplasms (NEN) for peptide receptor radionuclide therapy (PRRT). As the kidneys are organs at risk, this study evaluated whether renal uptake on pre-therapeutic SSTR-PET/CT reflects split or global renal function and correlates with renal absorbed dose during [177Lu]Lu-DOTA-TATE therapy. METHODS: In this retrospective study, 85 NEN patients treated with [177Lu]Lu-DOTA-TATE between 2013 and 2023 were included. All underwent SSTR-PET/CT using [18F]SiTATE, [68Ga]Ga-DOTA-TATE, or [68Ga]Ga-DOTA-TOC plus serum kidney function tests and [99mTc]Tc-MAG3 scintigraphy. Renal PET uptake was compared with serum and scintigraphic kidney parameters. In 30 patients, renal absorbed dose was estimated using post-treatment SPECT/CT. RESULTS: Renal uptake on SSTR-PET/CT moderately correlated with split renal function assessed by [99mTc]Tc-MAG3 across all tracers, particularly using SUVmean ([18F]SiTATE (r = 0.462; p = 0.010); [68Ga]Ga-DOTA-TATE (r = 0.515; p = 0.004); [68Ga]Ga-DOTA-TOC (r = 0.546; p = 0.004)). No relevant correlation was observed between total renal PET uptake and tubular extraction rate, eGFR, or serum creatinine. Renal PET uptake showed moderate correlations with mean absorbed doses in selected tracer cohorts ([18F]SiTATE; r = 0.585; p = 0.076; [68Ga]Ga-DOTA-TATE; r = 0.649; p = 0.049). A strong negative correlation between TER and absorbed dose was seen only for [18F]SiTATE (r = - 0.768; p = 0.010). CONCLUSION: SSTR-PET/CT showed moderate potential to estimate pre-therapeutic split renal function and renal absorbed dose. However, global renal function could not be reliably estimated using PET/CT. Larger studies are warranted to validate PET/CT-based kidney assessment for individualized PRRT planning.
引用
- Tiling M, Unterrainer LM, Siegmund SC, et al. Estimation of split renal function on PET using the SSTR-targeting radioligands [18F]SiTATE, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC in a theranostic setting. Eur J Nucl Med Mol Imaging. 2026. PMID: 42141279. doi:10.1007/s00259-026-07909-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。